105 related articles for article (PubMed ID: 3598074)
1. Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia.
Ciccarelli E; Mazza E; Ghigo E; Guidoni F; Barberis A; Massara F; Camanni F
J Endocrinol Invest; 1987 Feb; 10(1):51-3. PubMed ID: 3598074
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia.
Kletzky OA; Vermesh M
Fertil Steril; 1989 Feb; 51(2):269-72. PubMed ID: 2912773
[TBL] [Abstract][Full Text] [Related]
3. A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients.
Gianola D; Pedroncelli A; Montini M; Tengattini F; Pagani MD; Cortesi L; Cappi MP; Gherardi F; Lancranjan I; Pagani G
Gynecol Endocrinol; 1991 Sep; 5(3):213-6. PubMed ID: 1776507
[TBL] [Abstract][Full Text] [Related]
4. Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study.
Moro M; Maraschini C; Toja P; Masala A; Alagna S; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
Horm Res; 1991; 35(3-4):137-41. PubMed ID: 1806467
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
Lamberts SW; Quik RF
J Clin Endocrinol Metab; 1991 Mar; 72(3):635-41. PubMed ID: 1997518
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia.
Merola B; Colao A; Caruso E; Sarnacchiaro F; Lancranjan I; Lombardi G; Schettini G
J Endocrinol Invest; 1992 Mar; 15(3):173-6. PubMed ID: 1624676
[TBL] [Abstract][Full Text] [Related]
8. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
Verhelst JA; Froud AL; Touzel R; Wass JA; Besser GM; Grossman AB
Acta Endocrinol (Copenh); 1991 Oct; 125(4):385-91. PubMed ID: 1683503
[TBL] [Abstract][Full Text] [Related]
9. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
10. Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia.
Weingrill CO; Mussio W; Moraes CR; Portes E; Castro RC; Lengyel AM
Fertil Steril; 1992 Feb; 57(2):331-5. PubMed ID: 1735484
[TBL] [Abstract][Full Text] [Related]
11. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
[TBL] [Abstract][Full Text] [Related]
12. Medical management of hyperprolactinemia: a lower dose of bromocriptine may be effective.
Soto-Albors CE; Randolph JF; Ying YK; Riddick DH
Fertil Steril; 1987 Aug; 48(2):213-7. PubMed ID: 3609332
[TBL] [Abstract][Full Text] [Related]
13. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.
Ciccarelli E; Ghigo E; Mazza E; Andreis M; Massara F; Lancranjan I; Camanni F
J Endocrinol Invest; 1987 Apr; 10(2):179-82. PubMed ID: 3584856
[TBL] [Abstract][Full Text] [Related]
14. Double blind randomized study using oral or injectable bromocriptine in patients with hyperprolactinaemia.
Ciccarelli E; Grottoli S; Miola C; Avataneo T; Lancranjan I; Camanni F
Clin Endocrinol (Oxf); 1994 Feb; 40(2):193-8. PubMed ID: 8137517
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Ciccarelli E; Giusti M; Miola C; Potenzoni F; Sghedoni D; Camanni F; Giordano G
J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790
[TBL] [Abstract][Full Text] [Related]
16. Vaginal bromocriptine in hyperprolactinemic patients and puerperal women.
Jasonni VM; Raffelli R; de March A; Frank G; Flamigni C
Acta Obstet Gynecol Scand; 1991; 70(6):493-5. PubMed ID: 1763616
[TBL] [Abstract][Full Text] [Related]
17. Prolactin (PRL) response to oral or vaginal bromoergocriptine in hyperprolactinemic women.
Dash RJ; Ajmani AK; Sialy R
Horm Metab Res; 1994 Mar; 26(3):164. PubMed ID: 8005568
[No Abstract] [Full Text] [Related]
18. Vaginal bromocriptine--clinical and biochemical effects.
Ginsburg J; Hardiman P; Thomas M
Gynecol Endocrinol; 1992 Jun; 6(2):119-26. PubMed ID: 1502929
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy in hyperprolactinemic infertile women treated with vaginal bromocriptine: report of two cases and review of the literature.
Ricci G; Giolo E; Nucera G; Pozzobon C; De Seta F; Guaschino S
Gynecol Obstet Invest; 2001; 51(4):266-70. PubMed ID: 11408739
[TBL] [Abstract][Full Text] [Related]
20. Clinical and hormonal response to short-term intermittent versus continuous oral bromocriptine in hyperprolactinemic women.
Parra A; Crespo G; Coria I; Espinosa de los Monteros A
Int J Fertil Menopausal Stud; 1995; 40(2):96-101. PubMed ID: 7599666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
